In this context, the high sensitivity and specificity of current imaging techniques—particularly prostate-specific membrane antigen positron-emission tomography (PSMA-PET)—have enabled targeted salvage treatments, such as focal or oligometastasis-directed therapies, with the goal of delaying or preventing progression to metastatic disease. Here, FOLH1 is linked to metastatic neoplasm.